Showing results (501-510 of 5,984) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|March 31, 2019
GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP InhibitionShaolin Ma, Sunila Pradeep, Alejandro Villar-Prados, et al.
Molecular Cancer Therapeutics|March 31, 2019
Vemurafenib Inhibits Active PTK6 in PTEN-null Prostate Tumor CellsDarren J Wozniak, Ben Hitchinson, Milica B Gilic, et al.
Molecular Cancer Therapeutics|September 6, 2019
Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical ModelsThinh H Nguyen, Balakrishna Koneru, Sung-Jen Wei, et al.
Molecular Cancer Therapeutics|September 7, 2019
Transgelin 2 Promotes Paclitaxel Resistance, Migration, and Invasion of Breast Cancer by Directly Interacting with PTEN and Activating PI3K/Akt/GSK-3β PathwayLeichao Liu, Ti Meng, Xiaowei Zheng, et al.
Molecular Cancer Therapeutics|August 24, 2019
DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma ModelGulzar Ahmad, Gerardo G Mackenzie, James Egan, et al.
Molecular Cancer Therapeutics|May 22, 2015
23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal ToxicityTheresa Proia, Feng Jiang, Alisa Bell, et al.
Molecular Cancer Therapeutics|May 13, 2015
An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing SarcomaSalah-Eddine Lamhamedi-Cherradi, Brian A Menegaz, Vandhana Ramamoorthy, et al.
Molecular Cancer Therapeutics|May 13, 2015
Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian CancerMeghna Talekar, Qijun Ouyang, Michael S Goldberg, et al.
Molecular Cancer Therapeutics|May 8, 2015
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated PathwaysJonathan Rios-Doria, Darrin Sabol, Jon Chesebrough, et al.
Molecular Cancer Therapeutics|May 8, 2015
BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell VolumeNicholas Theodosakis, Matthew A Held, Alexander Marzuka-Alcala, et al.
Pageof 599